Fed’s Waller emerges as top candidate for Fed chair - report
ProAssurance Corp (NYSE:PRA)’s stock reached a new 52-week high, closing at 23.96 USD. With a market capitalization of $1.23 billion, this milestone reflects a significant upward trend, as the company’s stock has surged by 107.45% over the past year. According to InvestingPro data, the stock has demonstrated relatively low price volatility, making this sustained rally particularly noteworthy. The increase highlights investor confidence and strong performance in the market, with an impressive 60.82% gain over the past six months. Based on InvestingPro’s Fair Value analysis, the stock appears slightly overvalued at current levels. This 52-week high indicates a robust recovery and growth trajectory for the company, marking a pivotal moment for stakeholders and potential investors alike. Discover 10 additional key insights about ProAssurance with an InvestingPro subscription, including detailed analysis in the comprehensive Pro Research Report.
In other recent news, ProAssurance Corporation has made significant strides toward its acquisition by The Doctors Company. The U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, which is a key condition for the transaction’s completion. This development moves the acquisition closer to its expected closing in the first half of 2026, pending further regulatory approvals and customary closing conditions. Additionally, ProAssurance stockholders have shown strong support for the acquisition, with over 99% of votes cast in favor of the transaction. While the deal still requires clearance from insurance regulators in states where ProAssurance operates, it is not subject to a financing condition. These recent developments suggest that the acquisition process is progressing smoothly. The companies are awaiting the necessary regulatory approvals to finalize the transaction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.